Clinical TrialApr 22, 2026, 04:32 PM
Nexalin Advances HALO Clarity Pivotal Trial with Lindus Health
AI Summary
Nexalin Technology, Inc. has entered into a Scope of Work agreement with Lindus Health Limited, a UK-based clinical research organization. Under this agreement, Lindus Health will conduct the pivotal clinical trial for Nexalin's HALO Clarity device. The company will pay Lindus Health approximately $944,820 in direct fees, structured on a milestone basis, along with monthly pass-through expenses. This agreement marks a significant step forward in the development of the HALO Clarity device.
Key Highlights
- Entered Scope of Work with Lindus Health for HALO Clarity pivotal trial.
- Lindus Health to conduct the pivotal clinical study for the HALO Clarity device.
- Nexalin Technology to pay approximately $944,820 in direct fees.
- Payments are milestone-based, plus monthly pass-through expenses.